FDA nixes unapproved gout treatment; Interpol at work in Russia;

> The FDA has ordered a halt to the marketing of unapproved single-ingredient oral colchicine, a gout treatment. FDA release

> In Russia, Interpol has begun a large-scale anti-counterfeiting operation. Article

> Varichem Pharma in Zimbabwe has become the third sub-Saharan Africa company to gain WHO prequalification for a medicines product. Article

> BioMimetic is bringing the manufacture of its first U.S. product in-house via a $20-million investment to double the footprint of its Nashville-area facility. Story

> Medicago, a maker of virus-like particle vaccines, held a groundbreaking ceremony last week in Research Triangle Park, NC, for a commercial grade facility. Medicago release


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.